These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 32143887)

  • 1. Design and synthesis of novel 2-arylbenzimidazoles as selective mutant isocitrate dehydrogenase 2 R140Q inhibitors.
    Li Z; Wu X; Jia L; Li J; Zhang R; Tang H; Li Z; Bu H; Shen C
    Bioorg Med Chem Lett; 2020 May; 30(9):127070. PubMed ID: 32143887
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rationale design of novel substituted 1,3,5-triazine candidates as dual IDH1(R132H)/ IDH2(R140Q) inhibitors with high selectivity against acute myeloid leukemia: In vitro and in vivo preclinical investigations.
    Tawfik HO; Mousa MHA; Zaky MY; El-Dessouki AM; Sharaky M; Abdullah O; El-Hamamsy MH; Al-Karmalawy AA
    Bioorg Chem; 2024 Aug; 149():107483. PubMed ID: 38805913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of a selective inhibitor of IDH2/R140Q enzyme that induces cellular differentiation in leukemia cells.
    Chen J; Yang J; Wei Q; Weng L; Wu F; Shi Y; Cheng X; Cai X; Hu C; Cao P
    Cell Commun Signal; 2020 Apr; 18(1):55. PubMed ID: 32245484
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological characterization of TQ05310, a potent inhibitor of isocitrate dehydrogenase 2 R140Q and R172K mutants.
    Gao M; Zhu H; Fu L; Li Y; Bao X; Fu H; Quan H; Wang L; Lou L
    Cancer Sci; 2019 Oct; 110(10):3306-3314. PubMed ID: 31361380
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of a novel class of pyridine derivatives that selectively inhibits mutant isocitrate dehydrogenase 2.
    Wang F; Li Z; Zhang T; Yan G; Hu M; Zhao L; Zhao Y; Chen Y
    Chem Biol Drug Des; 2018 Jun; 91(6):1087-1093. PubMed ID: 29120536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-based design, synthesis and bioactivity evaluation of macrocyclic inhibitors of mutant isocitrate dehydrogenase 2 (IDH2) displaying activity in acute myeloid leukemia cells.
    Che J; Huang F; Zhang M; Xu G; Qu B; Gao J; Chen B; Zhang J; Ying H; Hu Y; Hu X; Zhou Y; Gao A; Li J; Dong X
    Eur J Med Chem; 2020 Oct; 203():112491. PubMed ID: 32679449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of novel enasidenib analogues targeting inhibition of mutant isocitrate dehydrogenase 2 as antileukaemic agents.
    Khalil AF; El-Moselhy TF; El-Bastawissy EA; Abdelhady R; Younis NS; El-Hamamsy MH
    J Enzyme Inhib Med Chem; 2023 Dec; 38(1):2157411. PubMed ID: 36629449
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Crystal structures of pan-IDH inhibitor AG-881 in complex with mutant human IDH1 and IDH2.
    Ma R; Yun CH
    Biochem Biophys Res Commun; 2018 Sep; 503(4):2912-2917. PubMed ID: 30131249
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allosteric inhibitor remotely modulates the conformation of the orthestric pockets in mutant IDH2/R140Q.
    Chen J; Yang J; Sun X; Wang Z; Cheng X; Lu W; Cai X; Hu C; Shen X; Cao P
    Sci Rep; 2017 Nov; 7(1):16458. PubMed ID: 29184081
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of new IDH2
    Chen X; Wu X; Gao J; Ying H; Dong X; Che J; Shen Z
    Arch Pharm (Weinheim); 2021 Mar; 354(3):e2000063. PubMed ID: 33184958
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential mitochondrial isocitrate dehydrogenase R140Q mutant inhibitor from traditional Chinese medicine against cancers.
    Lee WY; Chen KC; Chen HY; Chen CY
    Biomed Res Int; 2014; 2014():364625. PubMed ID: 24995286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of Mutated Isocitrate Dehydrogenase 1 in Cancer.
    Wu F; Cheng G; Yao Y; Kogiso M; Jiang H; Li XN; Song Y
    Med Chem; 2018; 14(7):715-724. PubMed ID: 29792149
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery and structure-activity-relationship study of novel conformationally restricted indane analogues for mutant isocitric dehydrogenase 1 (IDH1) inhibitors.
    Zheng Q; Tang S; Fu X; Chen Z; Ye Y; Lan X; Jiang L; Huang Y; Ding J; Geng M; Huang M; Wan H
    Bioorg Med Chem Lett; 2017 Dec; 27(23):5262-5266. PubMed ID: 29079473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of Novel Therapeutics Targeting Isocitrate Dehydrogenase Mutations in Cancer.
    Sharma H
    Curr Top Med Chem; 2018; 18(6):505-524. PubMed ID: 29773061
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of cancer-associated mutant isocitrate dehydrogenases: synthesis, structure-activity relationship, and selective antitumor activity.
    Liu Z; Yao Y; Kogiso M; Zheng B; Deng L; Qiu JJ; Dong S; Lv H; Gallo JM; Li XN; Song Y
    J Med Chem; 2014 Oct; 57(20):8307-18. PubMed ID: 25271760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biochemical, cellular, and biophysical characterization of a potent inhibitor of mutant isocitrate dehydrogenase IDH1.
    Davis MI; Gross S; Shen M; Straley KS; Pragani R; Lea WA; Popovici-Muller J; DeLaBarre B; Artin E; Thorne N; Auld DS; Li Z; Dang L; Boxer MB; Simeonov A
    J Biol Chem; 2014 May; 289(20):13717-25. PubMed ID: 24668804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A lymphoblast model for IDH2 gain-of-function activity in d-2-hydroxyglutaric aciduria type II: novel avenues for biochemical and therapeutic studies.
    Kranendijk M; Salomons GS; Gibson KM; Van Schaftingen E; Jakobs C; Struys EA
    Biochim Biophys Acta; 2011 Nov; 1812(11):1380-4. PubMed ID: 21889589
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 3-(7-Azaindolyl)-4-indolylmaleimides as a novel class of mutant isocitrate dehydrogenase-1 inhibitors: Design, synthesis, and biological evaluation.
    Hu Y; Gao A; Liao H; Zhang M; Xu G; Gao L; Xu L; Zhou Y; Gao J; Ye Q; Li J
    Arch Pharm (Weinheim); 2018 Oct; 351(10):e1800039. PubMed ID: 30113716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An integrative computational approach for the identification of dual inhibitors of isocitrate dehydrogenase 1 and 2 from phytocompounds of
    Bello RO; Okunlola ST; Kumar N; Victor O; Jimoh TO; Abdulsalam ZN; Kehinde IO; Umar HI
    J Biomol Struct Dyn; 2024 Sep; 42(14):7272-7288. PubMed ID: 37559488
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of Cancer-Associated Mutant Isocitrate Dehydrogenases by 2-Thiohydantoin Compounds.
    Wu F; Jiang H; Zheng B; Kogiso M; Yao Y; Zhou C; Li XN; Song Y
    J Med Chem; 2015 Sep; 58(17):6899-6908. PubMed ID: 26280302
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.